TABLE 2.
The relationship between therapeutic responses and clinicopathological factors.
| Clinicopathological factors | DCR | PD | P-value |
| Gender | |||
| Male | 11 | 6 | 0.61* |
| Female | 2 | 3 | |
| Histology | |||
| ADC | 5 | 5 | 0.67* |
| SCC | 8 | 4 | |
| Smoking history | |||
| Ever | 10 | 5 | 0.38* |
| Never | 3 | 4 | |
| Stage | |||
| IIIB | 3 | 2 | 1* |
| IV | 10 | 7 | |
| Mutational status in ctDNA | |||
| Negative | 7 | 0 | 0.017* |
| Positive | 6 | 9 | |
| bTMB | |||
| High | 4 | 4 | 0.66* |
| Low | 9 | 5 | |
| Lines of therapy | |||
| 2nd line | 9 | 5 | 0.66* |
| 3rd–6th line | 4 | 4 | |
| PFS (mean, 95% CI) | |||
| 2nd line | 9.03 (6.03∼12.02) | 3.19 (1.50∼4.88) | 0.010# |
| 3rd–6th line | 7.83 (0.62∼15.03) | 2.10 (0.17∼4.13) | 0.088# |
| TKI-related driver gene status | |||
| With mutations | 1 | 3 | 0.26* |
| Without mutations | 12 | 6 |
DCR, disease control rate; PD, progressed disease; ADC, adenocarcinoma; SCC, squamous cell carcinoma; ctDNA, circulating tumor DNA; bTMB, blood tumor mutational burden. ∗Calibrated Chi-square test or Fisher exact probability test; #unpaired t-test.